Post Reply 
[News] FDA Advisory Committee Recommends Approval of Qnexa
Author Message
ApneaNews Offline
Apnea News Correspondent
Advisory Members

Posts: 170
Joined: Feb 2012

Machine: IBM Selectric II
Mask Type: Full face mask
Mask Make & Model: 3M N95 (it gets dusty in the newsroom)
Humidifier: Sears Kenmore (circa 1979)
CPAP Pressure: 3200 psi
CPAP Software: Other Software

Other Comments: I report, therefore I am.

Sex: Undisclosed
Location: In the newsroom (where else?)

Post: #1
FDA Advisory Committee Recommends Approval of Qnexa
FDA Advisory Committee Recommends Approval of Qnexa

The US Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee recommended Qnexa, an investigational drug candidate being developed to address weight loss, type 2 diabetes, and obstructive sleep apnea, be granted marketing approval by the FDA for the treatment of obesity in adults. The Committee voted 20 to 2, on the recommendation for an approval based on a favorable benefit-risk profile.

"We are pleased with the panel's approval recommendation in support of the safety and efficacy of Qnexa," said Peter Tam, president of VIVUS. "We look forward to working with the FDA as they complete their evaluation. Obesity is a serious medical condition, and we are committed to making Qnexa available and providing physicians with a new medical treatment option in their battle with this public health epidemic."

The FDA is not bound by the recommendations of its advisory committees, but will consider the guidance during the review of the New Drug Application (NDA) that was submitted for Qnexa in October 2011. The scheduled Prescription Drug User Fee Act (PDUFA) date for Qnexa is April 17, 2012.

Qnexa is a once-a-day, proprietary, oral, controlled-release formulation of low-dose phentermine and topiramate, which is designed to decrease appetite and increase satiety (the sense of feeling full), the two main mechanisms that impact eating behavior. In phase 2 and 3 clinical data to date, patients taking Qnexa have demonstrated statistically significant weight loss, glycemic control, and improvement in cardiovascular risk factors, when used in combination with a diet and lifestyle modification program.

fair use from:

The above post may contain copyrighted material the use of which has not always been specifically authorized by the copyright owner. The material available is intended to advance the understanding of Sleep Apnea treatment and to advance the educational level of Sleep Apnea patients with regard to their health. Sometimes included is the full text of articles and documents rather than a simple link because outside links frequently "go bad" or change over time. This constitutes a "fair use" of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material in this post is distributed without fee or payment of any kind for research and educational purposes. If you wish to use copyrighted material from this post for purposes of your own that go beyond "fair use", you must obtain permission from the copyright owner.
02-29-2012 10:18 AM
Find all posts by this user Post Reply Quote this message in a reply

Donate to Apnea Board
Post Reply 

Possibly Related Threads...
Thread: Author Replies: Views: Last Post
Information [Admin Note] "Master Members" group name changed to "Advisory Members" SuperSleeper 0 704 05-17-2014 07:35 PM
Last Post: SuperSleeper
  [News] ATA Applauds House Committee Passage of Sleep Apnea Bill ApneaNews 1 1,404 09-23-2013 01:35 AM
Last Post: vsheline
Exclaimation Advisory: pulse oximeters can cause tissue damage Paptillian 6 3,176 07-18-2013 10:12 PM
Last Post: Paptillian

Forum Jump:

Who's Online (Complete List)